Loading…
Aceva, LLC was cited for marketing Sugar Balance as an unapproved drug by making disease claims on their website and social media platforms, including claims that the product improves insulin sensitivity, enhances blood sugar control, and helps decrease the body's need for insulin. The company violated the Federal Food, Drug, and Cosmetic Act by establishing through their marketing that Sugar Balance was intended for diagnosis, cure, mitigation, treatment, or prevention of disease—specifically diabetes and blood sugar disorders—without obtaining FDA approval as a new drug. The FDA and Federal Trade Commission jointly reviewed Aceva's websites and social media channels (Twitter and Facebook) in August 2021 and determined the product was being introduced into interstate commerce in violation of the Act.